Peritoneal Cancer

Given limited evidence, optimal management remains undefined however surgical cytoreduction continues to be the cornerstone of management across reported cases with adjuvant treatment individualised. Certain fertility preservation strategies are concurrently feasible within a multidisciplinary framework and should be considered given reported cases are predominantly seen in younger females.

P3, N=384, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

He achieved an excellent response to androgen deprivation therapy (ADT) combined with abiraterone and prednisone, maintaining an undetectable prostate-specific antigen (PSA) level for over 2 years...The patient transitioned to docetaxel plus ADT, resulting in symptomatic improvement and partial radiologic response...Second, standard markers such as PSA and immunohistochemistry may be misleading in atypical presentations. Finally, the case highlights the decisive role of molecular diagnostics, specifically NGS, in identifying tumor origin and preventing misdiagnosis.

However, these frequency estimates are derived from a subset of tested cases and should be interpreted within the context of variable molecular data reporting across studies. These findings highlight the potential value molecularly guided treatment strategies in this rare and lethal disease subtype.

We evaluated KRAS G12D -specific (MRTX1133) and pan-KRAS inhibitor (RMC-6236) in KRAS mut organoid and orthotopic PDX models of AA. Additionally, KRAS inhibition remodels TME and may enhance innate immune signaling. These findings support continued clinical development of KRAS inhibitors in AA and provide a rationale for combination strategies targeting resistance pathways and stromal remodeling.

The peritoneal location, particularly in association with endometriosis, raises the possibility of a peritoneal origin.ConclusionPeritoneal MLA is exceptionally rare. Pathologists should consider MLA in the differential diagnosis of peritoneal tumors, particularly those arising in the setting of endometriosis, to ensure accurate classification and appropriate clinical management.

P1, N=21, Completed, Oncoinvent Solutions AS | Active, not recruiting --> Completed | N=49 --> 21

P1, N=24, Not yet recruiting, Chong Kun Dang Pharmaceutical

P2, N=310, Recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | N=170 --> 310

P2, N=58, Active, not recruiting, OncoC4, Inc. | Trial primary completion date: Oct 2025 --> Aug 2026

P1/2, N=30, Recruiting, Imunon | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Dec 2026

The clinical future lies in interception: leveraging liquid biopsies for early detection, targeting both tumor-intrinsic vulnerabilities and permissive metastatic niches and adapting therapy dynamically to anticipate resistance. Understanding this genomic odyssey is essential for transforming mCRC into a controllable chronic condition.